Roche continues strong sales growth momentum of 7%

Swiss pharma giant Roche (ROG: SIX) today released financial results for the first nine months of 2025, showing that group sales grew by 7% to 45.98 million francs ($35.86 million) at constant exchange rates (CER; 2% in CHF), driven by high demand for its innovative medicines and diagnostics.

Pharmaceutical Division sales rose by 9% (4% in CHF) to 35.55 million francs due to continued high growth in sales of medicines for the treatment of severe diseases. Diagnostics Division sales increased by 1% (-4% in CHF) to 10.31 million francs as demand for pathology solutions and molecular diagnostics more than offset the impact of healthcare pricing reforms in China.

“This increase more than compensated for the total decrease of 0.5 billion francs (CER) in sales of the ‘loss of exclusivity (LOE)’ products – the decline in sales of Avastin (various types of cancer), Herceptin (breast and gastric cancer), MabThera/Rituxan (blood cancer, rheumatoid arthritis), Lucentis (severe eye diseases) and Esbriet (lung disease) was partially offset by an increase in sales of Actemra/RoActemra (rheumatoid arthritis),” Roche noted.